Sun Pharma acquires anti-inflammatory brands from Aksigen Hospital Care

Publicly-listed Sun Pharmaceutical Industries has acquired three anti-inflammatory drug brands - Disperzyme, Disperzyme-CD and Phlogam - from fellow Mumbai-based Aksigen Hospital Care. The drugs are for treating post-operative inflammation in patients undergoing minor surgery and dental procedures. It is claimed that Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (TBR) to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013